Actoplus Met is a drug owned by Takeda Pharmaceuticals Usa Inc. It is protected by 6 US drug patents filed from 2013 to 2016. Out of these, 2 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 03, 2029. Details of Actoplus Met's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Actoplus Met's patents.

Latest Legal Activities on Actoplus Met's Patents

Given below is the list of recent legal activities going on the following patents of Actoplus Met.

Event	Date	Patent/Publication
Today's Legal Activities
Payment of Maintenance Fee, 8th Year, Large Entity	21 Jan, 2023	US9101660
Payment of Maintenance Fee, 4th Year, Large Entity	31 Jan, 2019	US9101660
Post Issue Communication - Certificate of Correction	29 Jan, 2016	US9101660
Patent Issue Date Used in PTA Calculation	11 Aug, 2015	US9101660
Recordation of Patent Grant Mailed	11 Aug, 2015	US9101660
Email Notification	23 Jul, 2015	US9101660
Issue Notification Mailed	22 Jul, 2015	US9101660
Dispatch to FDC	07 Jul, 2015	US9101660
Application Is Considered Ready for Issue	06 Jul, 2015	US9101660
Issue Fee Payment Verified	01 Jul, 2015	US9101660

FDA has granted several exclusivities to Actoplus Met. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Actoplus Met, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Actoplus Met.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Actoplus Met's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Actoplus Met's generic, the next section provides detailed information on ongoing and past EP oppositions related to Actoplus Met patents.

Actoplus Met's oppositions filed in EPO

Actoplus Met has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 02, 2014, by Dr Klusmann Peter. This opposition was filed on patent number EP03751344A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP03751344A	Jul, 2014	Generics [UK] Limited	Patent maintained as amended
EP03751344A	Jul, 2014	Dr Klusmann Peter	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Actoplus Met is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Actoplus Met's family patents as well as insights into ongoing legal events on those patents.

Actoplus Met's family patents

Actoplus Met has patent protection in a total of 25 countries. It's US patent count contributes only to 10.0% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Actoplus Met.

Full family tree

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Generic Launch

About Actoplus Met

Actoplus Met is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for improving glycemic control in patients with type 2 diabetes already on a combination of pioglitazone and metformin or a thiazolidinedione (TZD) and metformin. Actoplus Met uses Metformin Hydrochloride; Pioglitazone Hydrochloride as an active ingredient. Actoplus Met was launched by Takeda Pharms Usa in 2005.